| 8:30AM - 9:30AM |
Session 1 - IBMS / ANZBMS - CABS joint Symposium
Chair: Toshi Yoneda, Rob Coleman |
| 9:30AM - 10:30AM |
Session 2 - IBMS / ANZBMS - CABS joint Orals
Chair: Graeme Jones, Jackie Center |
| 10:30AM - 11:00AM |
Refreshment Break |
| 11:00AM - 12:00AM |
Session 3 - IBMS / ANZBMS - CABS joint Orals II
Chair: Theresa Guise, Julian Quinn |
| |
Nicole Abdul: Inhibiting Glycogen Synthase Kinase-3 (GSK-3) Prevents the Development of Myeloma Bone Disease abs#008 |
| |
Andreas Evdokiou: Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumour growth and osteolysis in murine models of breast cancer development and progression. abs#009 |
| |
Andrew Douglas Chantry: Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the development of osteolytic bone disease in the 5T2MM murine model of myeloma abs#011 |
| 12:00PM - 1:00PM |
CABS Lunch |
| 1:00PM - 3:00PM |
Session 4 - Multiple Myeloma and Myeloproliferative Disease
Chair: Peter Croucher, Toshio Matsumoto |
| |
Masahiro Abe: Mutual interaction between myeloma cells and bone marrow microenvironment abs#013 |
| |
Louise Purton: The bone microenvironment and myeloproliferative disease abs#014 |
| |
Terry Golombick: The potential role of curcumin (diferuloylmethane) in patients with MGUS[Monoclonal Gammopathy of Undetermined Significance]. abs#015 |
| |
Michelle Lawson: Localising Individual Myeloma Cells to the Myeloma 'Niche' in Bone using Multiphoton Microscopy. abs#016 |
| |
David Smith: Monitoring myeloma development in bone using computational modeling abs#017 |
| |
Clive Buckle: Soluble Rank Ligand Produced by Myeloma Cells Contributes to Generalised Bone Loss in Multiple Myeloma. abs#018 |
| |
Cory Xian: Mechanisms and prevention of cancer chemotherapy-induced bone growth defects abs#019 |
| 3:00PM - 4:00PM |
Refreshments and Posters |
| |
Eitan Amir: Trials and Trepidations - Setting Up A Canadian Bone Metastasis Research Program abs#051 |
| |
Eitan Amir: Discordance Between Hormone Receptor Profile of Primary Breast Cancer and Metastatic Bone Disease: Should Bone Marrow Biopsy be Considered a Standard of Care? abs#052 |
| |
Vanessa Cheung: Identification of PTHrP regulated genes in breast cancer cells abs#053 |
| |
Peter Diamond: APO2L/trail inhibits tumour growth and bone destruction in a murine model of multiple myeloma abs#054 |
| |
anna georgieva: Modeling Wnt siganling pathway and its regulation of bone mass abs#055 |
| |
Hisatsugu Goto: Combined therapy with anti-parathyroid hormone-related protein antibody and zoledronic acid for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice . abs#056 |
| |
Agatha Labrinidis: Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in both an immunodeficient and immunocompetent animal model. abs#057 |
| |
Sally Martin: CXCL12 Expression is Regulated by HIF-2 a in Multiple Myeloma Plasma Cells abs#058 |
| |
Sang Ho Moon: Parachordoma of Inguinal Region abs#059 |
| |
Kimberly Morgan: Benign bone tumor excision and graft incorporation in 51 patients: average 22 months follow up. abs#060 |
| |
Carl A Power: Combined Docetaxel and Zoledronic Acid Treatment for Bone Metastatic Murine Prostate Cancer. abs#061 |
| |
Erik Thompson: Targeting Matrix Metalloproteinase-13 (MMP13) in Human Breast Cancer Model Systems abs#062 |
| |
Kate Vandyke: The tyrosine kinase inhibitor dasatinib dysregulates bone remodelling in vivo abs#063 |
| |
Mark Waltham: The antioxidant N-acetylcysteine and its therapeutic potential in breast-to-bone metastasis abs#064 |
| |
Alana Welm: The role of Macrophage Stimulating Protein in metastasis of breast cancer to bone abs#065 |
| |
Masahiro Abe: Bone marrow stromal cells suppress anti-myeloma effects of gammadeltaT cells abs#066 |
| 4:00PM - 6:00PM |
Session 5 - The Antitumor Potential of Bisphosphonates Realized?
Session sponsored by: Novartis Oncology
|
| |
Richard Bell: Osteonecrosis of the Jaw (ONJ): impact on management of skeletal complications of cancer. abs#020 |
| |
Philippe Clezardin: Insights into the Antitumor effects of Bisphosphonates from preclinical models abs#042 |
| |
Richard de Boer: Evidence of the Antitumour activity of Bisphosphonates in the adjuvant and metastatic settings abs#041 |
| 7:00PM - 11:30PM |
Conference Dinner & Awards |